Overall, our clinical database analysis indicated that RNF43 and AXIN2 overexpression may be a favorable prognostic factor, whereas HUNK overexpression may be a poor prognostic factor, suggesting potential therapeutic targets for patients with GC. This evidence concerns the gene RNF43 and gastric cancer.